vTv Therapeutics Inc (NASDAQ:VTVT) Director Paul G. Savas bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were purchased at an average cost of $5.18 per share, with a total value of $15,540.00. Following the acquisition, the director now directly owns 69,881 shares of the company’s stock, valued at $361,983.58. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of vTv Therapeutics Inc (NASDAQ:VTVT) traded down 1.34% on Monday, reaching $5.16. The company’s stock had a trading volume of 12,582 shares. The company’s market capitalization is $50.02 million. The stock has a 50-day moving average price of $5.71 and a 200-day moving average price of $5.56. vTv Therapeutics Inc has a 1-year low of $4.65 and a 1-year high of $7.50.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.44) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.44). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.20 million. On average, equities research analysts forecast that vTv Therapeutics Inc will post ($1.21) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/15/paul-g-savas-acquires-3000-shares-of-vtv-therapeutics-inc-vtvt-stock.html.

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in vTv Therapeutics by 1.8% in the first quarter. Geode Capital Management LLC now owns 37,976 shares of the biotechnology company’s stock worth $248,000 after buying an additional 676 shares during the last quarter. Vanguard Group Inc. boosted its stake in vTv Therapeutics by 0.3% in the first quarter. Vanguard Group Inc. now owns 289,391 shares of the biotechnology company’s stock worth $1,896,000 after buying an additional 932 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in vTv Therapeutics by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 22,780 shares of the biotechnology company’s stock worth $149,000 after buying an additional 1,305 shares during the last quarter. Renaissance Technologies LLC boosted its stake in vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after buying an additional 2,900 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in vTv Therapeutics during the first quarter worth $261,000. 12.18% of the stock is owned by institutional investors.

A number of equities research analysts recently commented on VTVT shares. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $24.00 target price on shares of vTv Therapeutics in a report on Thursday, March 30th. Zacks Investment Research downgraded vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, February 15th. Canaccord Genuity reaffirmed a “buy” rating on shares of vTv Therapeutics in a report on Tuesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of vTv Therapeutics in a report on Thursday, March 30th. Five research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average target price of $14.40.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

5 Day Chart for NASDAQ:VTVT

Receive News & Ratings for vTv Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.